Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe - Nasdaq

Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe  Nasdaq

HAIFA, Israel, April 29, 2019-- Pluristem Therapeutics Inc., a leading regenerative medicine company developing novel placenta-based cell therapy.